Core Viewpoint - The company has entered into a licensing agreement with Eisai Co., Ltd. for the development, production, and commercialization of Hanshuo® (sulunlimab injection) in Japan, focusing on oncology indications [1][2]. Group 1: Licensing Agreement Details - The company will receive an upfront payment of $75 million upon signing the licensing agreement [1]. - Regulatory milestone payments could total up to $80.01 million based on the achievement of various regulatory milestones for the licensed product in the region [1]. - Commercial sales milestone payments could reach approximately $233 million, contingent on the annual net sales levels of the licensed product in the region [1]. - The company will also receive royalties calculated as a double-digit percentage of the annual net sales of the licensed product in the region [1]. Group 2: Product Information and Market Expansion - Hanshuo® (sulunlimab injection) is an innovative anti-PD-1 monoclonal antibody developed by the company, already approved for multiple indications in mainland China, including treatments for various types of lung cancer and esophageal squamous cell carcinoma [2]. - The product has also received approvals in several countries/regions, including the EU, UK, and India, and has been granted orphan drug designation by regulatory authorities in the US, EU, Switzerland, and South Korea [2]. - The company is advancing multiple clinical trials for Hanshuo® and related combination therapies globally, covering a wide range of cancers [2]. - The collaboration with Eisai is expected to enhance the company's product accessibility and recognition in international markets, thereby creating conditions for sustained revenue growth [2].
复宏汉霖(02696)就汉斯状 治疗肿瘤适应症与Eisai 订立许可协议